fungal CYP51 (lanosterol 14α-demethylase)

Class

triazole antifungal (repurposed off-label for severe asthma with fungal sensitization / ABPA)

Pathway

inhibits fungal ergosterol synthesis, reducing the fungal allergen burden driving airway inflammation

Fungal CYP51, also called lanosterol 14α-demethylase, is an enzyme fungi require to convert lanosterol into ergosterol, the principal sterol that keeps fungal cell membranes stable and functional. Ergosterol plays the same structural role in fungi that cholesterol plays in human cells, but the fungal enzyme differs enough from its human counterparts that it can be selectively targeted by triazole antifungal drugs. Blocking CYP51 prevents ergosterol synthesis, causing toxic sterol intermediates to accumulate and disrupting the fungal cell membrane, which impairs fungal growth and survival. Beyond treating invasive or superficial fungal infections, this mechanism has a second, less obvious application: in certain chronic airway diseases, persistent colonization of the airways by molds such as Aspergillus species can drive ongoing allergic and inflammatory responses that worsen asthma control. Reducing the burden of viable fungus in the airways, by inhibiting fungal ergosterol synthesis, can lower the antigenic stimulus that perpetuates this inflammation. This rationale underlies the use of triazole antifungals in severe asthma associated with fungal sensitization and in allergic bronchopulmonary aspergillosis, where the antifungal action is being applied indirectly, to dampen an immune-driven airway disease rather than to treat an active infection.